KI-3106 is under clinical development by Kuhnil Pharmaceutical and currently in Phase I for Hyperlipidemia. According to GlobalData, Phase I drugs for Hyperlipidemia have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KI-3106’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KI-3106 overview
KI-3106 is under development for the treatment of hyperlipidemia.
Kuhnil Pharmaceutical overview
Kuhnil Pharmaceutical (Kuhnil) is a pharmaceutical company that develops, manufactures and markets antibiotics and medicinal products. The company provides products such as antibiotics, neurology products, endocrinology systems products, musculoskeletal system products, respiratory system products, anti-viral agent products and digestive system products. Its offerings include amocla tab, netilmicin kuhnil injection, wellcon tab, omacor and glimepiride kuhnil tab; and medical device products, among others. Kuhnil is headquartered in Seoul, South Korea.
For a complete picture of KI-3106’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
